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Abstract: Enzyme catalyzed reactions are rapidly becoming an invaluable tool for the synthesis of
many active pharmaceutical ingredients. These reactions are commonly performed in batch, but
continuous biocatalysis is gaining interest in industry because it would allow seamless integration of
chemical and enzymatic reaction steps. However, because this is an emerging field, little attention
has been paid towards the suitability of different reactor types for continuous biocatalytic reactions.
Two types of continuous flow reactor are possible: continuous stirred tank and continuous plug-flow.
These reactor types differ in a number of ways, but in this contribution, we focus on residence time
distribution and how enzyme kinetics are affected by the unique mass balance of each reactor. For the
first time, we present a tool to facilitate reactor selection for continuous biocatalytic production
of pharmaceuticals. From this analysis, it was found that plug-flow reactors should generally be
the system of choice. However, there are particular cases where they may need to be coupled
with a continuous stirred tank reactor or replaced entirely by a series of continuous stirred tank
reactors, which can approximate plug-flow behavior. This systematic approach should accelerate the
implementation of biocatalysis for continuous pharmaceutical production.
Keywords: continuous process; enzyme; residence time distribution; kinetics; reactor selection;
biocatalysis; flow chemistry
1. Introduction
As the pharmaceutical industry moves towards flow chemistry [1], the real advantage of
continuous manufacturing is that common (and even standardized) technologies will start to be used
for development and ultimately production. For example, production can use scaled-out versions of
the identical tubular reactors which were run in the laboratory. The use of such common technologies,
will enable enormous savings to be made in development time, meaning that processes can be
implemented more quickly, and products launched into the market earlier. These are major drivers
in virtually all pharmaceutical companies and so the field has grown considerably in recent years.
The complementary field of biocatalysis has also grown tremendously in the last decade. This has been
fueled firstly by protein engineering developments [2–5],which allow the individual tuning of catalytic
properties of enzymes, and secondly by the ability to operate cascades of enzymes [6–8] under similar
conditions. Additionally, biocatalysis offers the possibility of cutting the number of process steps [9].
Many in the biocatalysis field therefore believe it timely to investigate flow biocatalysis [10,11], not
least because this enables the smooth integration of chemical and biocatalytic methods together in
continuous processes [12,13]. Indeed, this special issue is testament to the interest in this field. There are
already some superb examples of flow biocatalysis both in the area of enzyme characterization and
property measurements [14,15], as well as development and production [16,17]. Nevertheless, an
often-cited challenge is that biocatalytic reactions in general are rather slow (compared to their chemical
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counterparts) and thereby the use of flow technology is hard to justify. In reality, the arguments for
flow technology are perhaps a little different for enzymes and, in this brief review, we will discuss
the issue of reactor selection, in order to capitalize upon the benefits of both flow technology and
biocatalysis. Downstream unit operations are not included in this discussion.
2. Reactor Types
Figure 1 shows schematic diagrams of the three ideal reactor types, namely the batch stirred
tank reactor (BSTR), the continuous stirred tank reactor (CSTR) and the continuous plug-flow reactor
(CPFR). The characteristics of these reactors have been described in extensive detail elsewhere [18] and
will therefore be only briefly summarized here.
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Figure 1. Reactor schematics, substrate concentration (CS) profiles and design equations for: (a) batch 
stirred tank reactor (BSTR), (b) continuous stirred tank reactor (CSTR) and (c) continuous plug-flow 
reactor (CPFR). 
The design equations for each of the reactors in Figure 1 can be used to determine the 
concentration of enzyme (E) required to achieve a desired fractional conversion of substrate (X) for a 
given initial or feed substrate concentration (CS0). In a BSTR, the time of reaction (t) and reaction 
volume (V) are also required, whilst for CSTRs and CPFRs the volumetric flowrate through the 
reactor (Q) is needed. KM is the affinity constant of the enzyme towards the substrate and kcat is its 
turnover number. 
In a BSTR, the mechanically stirred vessel is first filled with substrate and enzyme, to initiate the 
reaction, after which no material is removed until the reaction is stopped. BSTRs are well-mixed 
reactors, meaning that concentrations are the same regardless of location within the reactor. Typical 
enzyme kinetics follow Michaelis–Menten behavior, where rate is independent of substrate (zero 
order) at high concentrations but becomes proportional to the amount of substrate (first order) at 
lower concentrations, with a transition in between. This means that in a BSTR the substrate is initially 
consumed quickly, whilst later in the reaction, as it enters the first order regime, the reaction rate 
slows, as illustrated by the substrate concentration profile in Figure 1a. However, given sufficient 
time in the reactor, complete conversion can be achieved, provided the equilibrium is favorable. 
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of e zyme (E) required to achi ve a desired fractional conversion of substrate (X) for a given initial
or fe d substrate concentra ion (CS0). In a BSTR, the time of reac ion (t) and reacti volume (V) are
als required, whilst fo CSTRs and CPFRs the volumetric flowrate thro gh he reactor (Q) is needed.
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In a BSTR, the mechanically stirred vessel is first filled with substrate and enzyme, to initiate
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consumed quickly, whilst late i the reaction, as it enters the firs order regime, the eactio rate
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BSTRs are commonly used for biocatalytic reactions [19,20] due to their simplicity and flexibility.
For instance, substrate concentrations can be kept below toxic or inhibitory levels by adopting a
fed-batch approach [21,22] where substrate is fed to the reactor, resulting in a reaction volume that
increases with time. Additionally, pH changes caused by the biocatalytic reaction can be neutralized
through the addition of an acid or base to maintain the optimal pH of the enzyme.
The design of a CSTR is similar to that of a BSTR, except that material is continuously added
to, and removed from, the reactor such that the working volume remains constant. In this case, the
biocatalyst must either be fed continuously to the reactor (to make up for loss of catalyst in the effluent)
or it must be retained within the reactor by immobilization and/or partially permeable membranes.
Like BSTRs, CSTRs are well-mixed and so the reactor contents and effluent are homogenous. However,
since there must be enough substrate in the reactor to achieve an adequate reaction rate, the effluent
will always contain some substrate and so full substrate conversion is not possible [23]. This trade-off
between reaction rate and conversion is an important characteristic of CSTRs. Furthermore, since
the reactor contents are homogenous, the substrate concentration, and subsequently the reaction rate,
throughout the reactor remain constant with respect to time, as shown in the profile in Figure 1b.
In a CPFR, reactants are pumped into a long tubular reactor where, unlike stirred tanks, material
flowing through does not mix with any material flowing ahead of it, or behind it. This results in
concentration gradients over the length of the reactor, identical to the concentration gradients over time
in a BSTR. Therefore, if the reactor is sufficiently long, the substrate can be fully converted. For this
reason, in Figure 1c the concentration profile is given with respect to length, since the time material
spends in a CPFR is simply a function of the reactor length and volumetric flowrate. Although it
is possible to operate a CPFR with a soluble catalyst, biocatalysts are typically immobilized onto
the reactor wall or on particles of a carrier material, which are then packed into a tube to form a
continuous packed-bed reactor (CPBR) [24] that exhibits plug-flow behavior. However, this can
potentially introduce mass transfer limitations and large pressure drops over the reactor [25].
3. Batch vs. Continuous
There are many considerations which need to be evaluated when selecting the type of reactor to
use. However, even for simple single product reactions in a single liquid phase, two considerations
which are always of relevance are the residence time distribution (RTD) and the kinetics of the enzyme
catalyzed reaction. BSTRs and CPFRs have identical kinetic behavior and both afford good control over
RTDs. Consequently, it would appear that there is little motivation to invest in the shift from batch
operation to continuous since both give the same result. However, much research has highlighted the
benefits of continuous biocatalysis over batch processing, for both production as well as research and
development, and these are summarized in Figure 2 [26–28]. Nonetheless, it has also been shown that,
for single-phase homogenous reactions, the differences in performance between batch and continuous
reactors at the laboratory scale are negligible [29]. Therefore, in such instances, shifting from batch
to continuous would appear to be a time-consuming and resource-intensive process that yields few
improvements. But, at production scales, where mixing and heat transfer in large batch reactors are
less efficient, shifting to continuous operation could be beneficial. Additionally, steady-state operation
of a continuous reactor affords simpler control and greater consistency than a dynamic batch process
at large scales.
Moreover, active pharmaceutical ingredients (APIs) are often the products of numerous reaction
steps. Some of these reaction steps, especially those involving optically active compounds, may
be biocatalytic, but many reactions are still more efficient using chemical catalysts. Chemocatalytic
reactions are frequently operated continuously to benefit from rapid mixing and heat transfer [30],
particularly in the case of exothermic reactions, or to avoid the storage of unstable or toxic intermediates.
Therefore, when selecting a reactor for a biocatalytic reaction that has to be integrated into a combined
chemo/biocatalytic reaction sequence [31–33], opting for a continuous approach may be more practical,
potentially allowing for end-to-end manufacturing that could even include downstream processing
Catalysts 2019, 9, 262 4 of 17
and formulation [34]. For this reason, it may also make more sense to use continuous reactors for
research and development in the pharmaceutical industry, as it simplifies the transition to production
scale through the process of scale-out, reducing time-to-market.Catalysts 2019, 9, x FOR PEER REVIEW 4 of 17 
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4. Residence Time Distribution
Residence time defines the length of time materi l is in a reactor. For an ideal BSTR it is simply
the tim fr m the addition of the final r agent (usually biocatalyst) t the quenc ing time of the
reaction. In other words, all material is in the reactor for the same length of time and can be said to
have a defined residence time. If this time is sufficiently long, then all the re ctant will h ve been
converted to product. Therefore, in the production of APIs, batch reactors have freque tly been
used simply because complete conversion was achievable. Moreover, if some substrate remains at
the end of the reaction, ore catalyst can be added to complete the co versio . This flexibility is
very attractive. Even in cases where the equilibrium prevents complete conversion of substrate to
product, all material has an identical residence time and thereby the reaction mixture has a defined
conversion. For more complex reactions (with multiple reactants, products or phases) this is critical,
because otherwise what might leave the reactor is a variable mixture of compounds that complicates
downstream processing. Small-molecule APIs are complex, and their production is strictly regulated
(e.g., by the Federal Drug Administration or European Medicines Agency). For this reason, there is
a demand for precision che istry in the pharmaceutical industry to achieve high product quality
in a reproducible manner, ensuring the safety of the patient. It is for this reason that enzymes are
particularly attractive due to their high selectivity [35], compared to most conventional catalysts,
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which minimizes by-product formation. Additionally, they operate at mild conditions [36] which also
greatly reduces the occurrence of spontaneous degradation of reactants, intermediates or products.
This allows for the precise production of APIs with simpler downstream processing steps. However,
to truly capitalize upon this, the reactor should also give a precise residence time. In other words, a
precision catalyst used in a precision reactor. In this way the benefit of flow biocatalysis becomes clear.
Residence time is an important characteristic of any reactor. It is desirable to have a well-defined
residence time for accurate control of reactions. In an ideal CPFR, where no back-mixing occurs,
material exits the reactor in the same order as it enters with a single residence time (τ) which can easily
be calculated from the volume of the reactor and the volumetric flowrate, as follows:
τ =
V
Q
(1)
The ideal BSTR and CPFR are the only two cases where a reactor has a single residence time.
For all other reactor types and configurations, multiple residence times exist and so residence times
are typically expressed as a function of time, known as the residence time distribution. For instance,
the RTD of the ideal BSTR (or ideal CPFR) is represented mathematically by the following Dirac delta
function, shown graphically in Figure 3:
E(t) = δ(t− τ) (2)
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In an ideal CSTR it is assumed that mixing is complete and instantaneous, such that the 
composition of the entire reactor volume and the reactor outlet are homogenous. As a result, some of 
the feed molecules exit the reactor immediately, since fluid is constantly being removed at the outlet, 
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In an ideal CSTR it is assumed that mixing is complete and instantaneous, such that the
composition of the entire reactor volume and the reactor outlet are homogenous. As a result, some of
the feed molecules exit the reactor immediately, since fluid is constantly being removed at the outlet,
whilst others remain in the reactor almost indefinitely. Therefore, the RTD can be represented by an
exponential decay function (Equation (3)), illustrated in Figure 4, although the mean residence time
can still be calculated using Equation (1).
E(t) =
1
τ
e(
−t
τ ) (3)
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5. Enzyme Kinetics 
Enzyme kinetics are often modeled using the basic Michaelis–Menten equation, shown below. 
Modified versions of this equation also exist to describe more complex systems, such as those with 
substrate or product inhibition, or multiple substrates or products. 
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V୫ୟ୶ = kୡୟ୲E (5) 
Equation (4) relates the reaction rate (v) to the substrate concentration. The maximum rate of the 
enzyme reaction (Vmax) is dependent on the turnover number of the enzyme and its concentration. 
The affinity constant of the enzyme towards a specific substrate, KM, corresponds to the substrate 
concentration at which the initial rate will be half of the maximum rate. Therefore, to achieve the 
maximum rate of an enzymatic reaction, the substrate concentration must be sufficiently high 
(relative to its KM) that the rate equation approximates the following zero order form: 
Cௌ ≫ K୑ 
v ≈ V୫ୟ୶ = kୡୟ୲E (6) 
If an enzyme has a very high affinity towards a particular substrate, characterized by a very low 
KM, the maximum rate of the enzymatic reaction can still be achieved at low substrate concentrations. 
This is a highly desirable scenario because it means that the enzyme can likely be used effectively 
regardless of reactor type. This can be illustrated by dividing the design equation of a CSTR 
(Figure 1b) with that of a CPFR (Figure 1c) to determine the ratio of enzyme concentrations 
(ECSTR/ECPFR) required to reach a desired fractional conversion, plotted in Figure 5. It can be seen that, 
to reach high fractional conversions, much higher enzyme concentrations are required in a CSTR than 
a CPFR unless the substrate concentration in the feed is a few orders of magnitude higher than the 
affinity constant of the enzyme. For this reason, protein engineering efforts should be focused on 
increasing the affinity of enzymes towards industrially attractive molecules [37,38]. In the meantime, 
however, enzymes generally have low affinities towards pharmaceutical intermediates due to their 
complex, non-native structures. Therefore, for pharmaceutical production in particular, the choice of 
reactor can greatly affect the reaction rates that can be achieved in a biocatalytic reaction. 
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Enzyme kinetics are often modeled using the basic Michaelis–Menten equation, shown below.
Modified versions of this equation also exist to describe more complex systems, such as those with
substrate or product inhibition, or multiple substrates or products.
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Vmax = kcatE (5)
Equation (4) relates the reaction rate (v) to the substrate concentration. The axi u rate of the
enzy e reaction (V ) is dependent on the turnover nu ber of the enzy e and its concentration.
The affinity constant of the enzy e to ards a specific substrate, KM, corresponds to the substrate
concentration at hich the initial rate ill be half of the axi u rate. Therefore, to achieve the
axi u rate of an enzymatic reaction, the substrate concentration must be sufficiently high (relative
to its KM) that the rate equation approximates the following zero order form:
CS  KMv ≈ Vmax = kcatE (6)
If an enzyme has a very high affinity towards a particular substrate, characterized by a very low
KM, the maximum r te of the enzymatic reaction can still be achieved t low subst at concentrations.
This is a highly desirable scenario because it me s hat the enzyme can likely be used ffectively
regardless of reactor type. This can be illustrated by dividing the design equat on of a CSTR (Figure 1b)
with that of a CPFR (Figure 1c) to determine the ratio of enzyme concentrations (ECSTR/ECPFR) required
to reach a desired frac ional conversion, plotted in Figur 5. It can be seen that, to reach high fractional
conversions, m ch higher enzyme concentrations are required in a CSTR than a CPFR unl ss the
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Figure 5. Enzyme concentrations required in a CSTR vs. a CPFR to achi ve a desired fractional
conversion of substrate.
For instance, in a CSTR, substrate is fed into a much larger, well-mixed volume. This means the
reaction takes place at a single, constant substrate concentration far more dilute than that of the feed,
resulting in reduced rates throughout the reactor. In contrast, the substrate concentration in a CPFR is
equal to that of the feed at the inlet, where the enzyme can operate closer to its maximum rate, and
progressively decreases across the length of the reactor, as does the reaction rate. This is typically a
more effective way of using the catalyst. As expressed earlier, this kinetic behavior is identical to that
of a biocatalytic reaction in a BSTR [18].
Enzyme inhibition by substrate or product is also very important to consider when selecting a
reactor for biocatalysis. On the one hand, if the enzyme is inhibited by high concentrations of the
substrate, the substrate dilution that occurs in a CSTR may be desirable, whereas the high initial
substrate concentration in a CPFR could have a negative impact. On the other hand, if the enzyme is
inhibited by the product, operating in a CSTR is undesirable as the homogeneity guarantees inhibition
throughout the reactor unless a much larger, more dilute reaction volume is used, which would
increase capital costs as well as the cost of downstream processing. Conversely, in a BSTR product
inhibition would only become problematic towards the end of the reaction. Likewise, in a CPFR the
rate would only be severely inhibited towards the end of the reactor, whilst maintaining a smaller,
more concentrated and cost-effective volume. The concentrations of substrate and product throughout
the reactor also influence the thermodynamic equilibrium of the reaction, but this has been discussed
in detail elsewhere [39].
The difference in capital costs between a CSTR and CPFR is best demonstrated with an
example. One of the most successful instances where a biocatalytic reaction has been implemented
in the pharmaceutical industry is the use of a highly engineered transaminase in the production of
sitagliptin [40]. The kinetic parameters of this enzyme have not been published. However, another
transaminase from Halomonas elongata (HEWT), which has been characterized, was recently used for
the continuous production of a ines at laboratory scale [41]. The turnover number of this enzyme was
found to be 0.094 s−1, and its KM values were 2.57 mM and 0.56 mM towards (S)-1-phenylethylamine
(amino donor) and pyruvate (amino acceptor), respectively, for the production of acetophenone at
25 ◦C [42]. Due to the high affinity of the enzyme towards pyruvate, it will be assumed that pyruvate
is supplied in sufficient excess such that the reaction rate is only dependent on the concentration of
(S)-1-phenylethylamine, according to Equation (4). Equation (7) shows how the Michaelis–Menten
expression can be transformed into a function of the fractional conversion, where FS0 is the inlet molar
flowrate of substrate.
v =
kcatE
FS0
Q (1− X)
KM +
FS0
Q (1− X)
(7)
A typical industrial enzyme concentration of 1 g/L has been assumed as well as a desired annual
production target of 100 kg, with a final product concentration of 10 g/L. Figure 6 shows the Levenspiel
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plot for this reaction, which can be used to determine the reactor volume required to achieve a desired
conversion in a continuous reactor with these conditions [43]. For a CSTR, the required volume is equal
to the area of a rectangle with a height of FS0/v and a width of X, whereas for a CPFR, the required
volume is the area under the curve. It is clear from Figure 6 that a similar volume would be required
for both reactors to achieve most fractional conversions. In fact, only 2.5 L more volume would be
required in a CSTR than a CPFR to achieve 80% substrate conversion. However, in most biocatalytic
reactions the only difference between the substrate and product is a single functional group, which
can make separating them extremely challenging. Therefore, to avoid adding more complexity to the
downstream process it is best to aim for complete conversion of the substrate and this is where the
gap between the CSTR and the CPFR becomes apparent. From Figure 6, it can be calculated that, to
achieve 99% substrate conversion, a CPFR with a volume of 38 L would be sufficient, but a CSTR
would require a volume of 134 L, nearly 4 times larger. This problem becomes significantly worse if a
conversion of 99.9% is desired, a perfectly common target in the pharmaceutical industry, in which case
a CSTR would require 23 times more volume than a CPFR, greatly increasing capital and downstream
processing costs.
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Figure 6. Levenspiel plot for the production of acetophenone from (S)-1-phenylethylamine and
pyruvate by an amine transaminase from Halomonas elongata (HEWT).
6. pH Control and Multiphase Systems
Much of the previous discussion has shown that CPFRs are generally better suited for continuous
biocatalytic production f pharmaceuticals than CSTRs. Nevertheless, CPFRs nd CPBRs do have s me
limitations th may recl de their use with cert in systems. For instanc , although resi ence time
and t mperature re easily controlled in these reactors, control of pH across the length of the reactor
is often more challenging due to the concentration gradi nts that arise from the lack of mixi [44].
To overc me this probl m, engineere enzym s that can olerate th range of pH expected to occur
across the react r would be required. Alter atively, th effluent from the CPFR can be recycl d through
a CSTR where acid or base can be added to adjust the pH back to t e optimal value, as illustr ted
in Figure 7. Here, the well-mixed behavior of a CSTR is xtremely beneficial to quickly c unteract
pH change . Another possibility is to operate ultiple shorter CPFRs in series sinc the performance
will be the same as a single long CPFR. This allows additi nal pH adjustments to be made b tween
CPFRs, as show in Figur 8. This configuration could also allow intermediate substrate feedi g to
avoid substrate inhibition.
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7. Reactor Selection
The analyses of reactor configurations in Sections 4–6 are established, even if not widely discussed
in the scientific literature. However, we have also taken inspiration from this to develop a reactor
selection tool, so that for the first time, decisions about continuous biocatalytic reactors can be made on
a rational basis. To effectively use this tool, a number of prerequisites should be satisfied, namely that
the enzyme of interest has been characterized, the operating conditions (temperature, pH, co-solvents
etc.) have been set and the enzyme has been shown to be stable at these conditions for a sufficient
duration, which is case dependent. Additionally, it is recommended that the main limitations of the
enzyme [49] are identified and its performance is compared with relevant economic targets [50], but
this is outside the scope of this article.
Figure 10 shows a proposed workflow for selecting a continuous reactor configuration. Initially, it
is important to assess whether the enzyme or downstream purification is likely to be the dominant
operating cost of the process, since the objectives in each case are different. For example, if an
expensive enzyme is required then it is crucial to select a reactor configuration that will make the
most effective use of the enzyme kinetics. However, if the enzyme is inexpensive, relative to product
isolation and purification, the kinetics become less important since higher enzyme concentrations can
always be used to increase reaction rates. In such a case, it would instead be desirable to simplify
downstream processing by ensuring that effluent concentrations do not vary significantly to maintain
the necessary driving force for separation. This can be achieved by having a well-defined residence
time. Additionally, if possible, the substrate should be fully converted to avoid difficult separations.
If the enzyme is determined to be the dominant operating cost, the next step is to calculate the
required substrate concentration from the desired product concentration and reaction yield. For high
value products like pharmaceuticals a product concentration of at least 60 g/L is generally economically
feasible [50]. Once the substrate concentration is determined it should be compared to the affinity
constant of the enzyme to determine whether it is high enough for the enzyme to operate close to its
maximum rate. Since enzymatic reactions typically take place in aqueous environments, the water
solubility of the substrate may be a limiting factor, especially for large, complex, organic molecules
like pharmaceutical intermediates. Therefore, organic solvents may be required to increase substrate
solubility. Protein engineering has recently been applied to allow enzymes to operate in the presence
of organic solvents [51]. However, the ideal scenario would be to have enzymes operating in neat
substrate, completely solvent-free [52]. If the substrate concentration is not above the affinity constant,
it means that the enzyme will not even operate at half of its maximum rate, which is far too ineffective
for many industrial processes. Consequently, it would be better to continue engineering the enzyme to
reduce its KM until it is below the required substrate concentration.
If the substrate concentration is sufficient for good rates, the next step is to determine whether the
enzyme is inhibited by the substrate or product. If the enzyme is inhibited at substrate concentrations
close to the desired feed concentration, a CPFR can be used if it is fed with a lower substrate
concentration at multiple points along the reactor. However, the lack of mixing could make it difficult
to radially disperse the substrate in reactors with larger diameters, especially if the substrate is fed
from one side of the reactor. Therefore, a better alternative may be to operate a series of shorter CPFRs,
using the same total reaction volume, with a substrate feed between each reactor. If the product inhibits
the enzyme at the desired product concentration, a CPFR can be used to ensure that product inhibition
is only severe towards the end of the reactor. Alternatively, plug-flow behavior can be approximated
with a series of CSTRs, each with a higher product concentration than the previous. In this way, only
the last reactors should be severely inhibited. Nevertheless, the last reactor in the series should be
equipped with a means of selectively removing the product to prevent complete inhibition in the
reactor and avoid substrate in the effluent.
If downstream processing is found to have a higher overall cost contribution than the enzyme,
plug-flow behavior is critical for approaching full conversion; so too having good control over the
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residence time, and consequently the concentration profiles at the outlet. Therefore, a CPFR would be
the most appropriate reactor configuration.
Finally, the need for pH control and/or multiple phases should be considered. In both of these
cases, good mixing is required to neutralize pH changes or generate high interfacial areas between
phases. For multiphase reactions, a series of CSTRs should be used to approximate plug-flow behavior
while still allowing sufficient dispersion of the phases. This configuration would also be beneficial for
pH control because it provides multiple acid/base feed points. Alternatively, a CPFR can be coupled
with a recycle loop through a CSTR where pH can be controlled, although the presence of a recycle
complicates the process.
8. Immobilization
Due to the high cost of enzymes, it is desirable to recycle them for continuous operation, provided
they are stable enough for repeated use. Isolation of the enzyme downstream of the reactor, using
selectively permeable membranes, is one possibility, but introduces an additional unit operation and
further complexity to the process. A better alternative is to retain the enzyme within the reactor.
This can be done by placing membranes at the reactor outlet, however, fouling of the membrane and
concentration polarization are likely to become problematic [53]. For this reason, the most common
method of retaining enzymes within a reactor is by binding them to larger carrier particles that are
easier to separate from the reactor effluent than the soluble enzyme. Recently, the use of paramagnetic
nanoparticles as supports has received much attention due to their high specific surface areas and
simple retention within the reactor by a magnetic field [54]. Numerous methods and support materials
have been described for the immobilization of a wide variety of enzymes [55]. Depending on the
support material used, immobilization can improve the stability of an enzyme towards harsher
operating conditions, such as elevated temperatures or the presence of organic co-solvents [56–58],
since bonds are formed between the enzyme and the support. However, in some cases, these bonds,
particularly strong covalent bonds, may prevent the enzyme from adopting a more stable conformation
or one that is required to catalyze the desired reaction and so, immobilization of an enzyme can also
negatively affect its stability or activity [59,60]. Physical adsorption is an alternative for immobilizing
enzymes without forming such strong bonds [61] but this makes it easier for the enzyme to leach off the
support during reactor operation. Affinity immobilization, whereby enzymes are engineered to contain
specific tags [62] that bind very selectively to ligands on specialized support materials, minimizes
leaching and maintains the flexibility of the enzyme so that activity loss is reduced. This method
of immobilization also ensures that only the desired enzyme binds to the support instead of other
proteins or impurities that may be present in crude cell extracts.
In stirred tank reactors, whether they are operated in batch or continuously, the use of immobilized
biocatalysts is often limited because the catalyst loading in the reactor is restricted to about 10% (v,v),
compared to 60% (v,v) in a CPBR [18]. This is because the shear forces from stirring [63] may break apart
the carrier material, making the biocatalyst difficult to separate from the reaction media and potentially
contaminating the effluent. Loss of biocatalyst in the effluent may also reduce the productivity of a
CSTR. Cross-linked enzyme aggregates (CLEAs) [64] are a more suitable form of immobilization for use
in stirred tank reactors [65,66] due to their smaller size compared to typical carrier-bound biocatalysts.
Although immobilization has proven to be advantageous in some cases, it is important to
recognize that the support and immobilization process add additional cost to the biocatalyst and
this should always be taken into consideration when assessing the feasibility of a process. Furthermore,
although most immobilization supports allow for high protein loadings due to their large specific
surface areas, internal diffusion limitations frequently make such high loadings ineffective [67,68]. As a
result, immobilization often limits the amount of enzyme that can be loaded into a reactor, compared to
soluble enzymes. Nevertheless, as protein expression and engineering continue to improve, the costs
of enzymes may decrease until eventually it becomes feasible to utilize soluble enzymes in continuous
processes [69–71]. This would be especially attractive for the pharmaceutical industry, where the high
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value of the products can help offset the cost of the biocatalyst, to simplify production and downstream
processing. Additionally, the enzyme would only need to be stable at the desired operating conditions
for the length of the residence time in the reactor.
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9. Outlook
In this review, some important criteria have been investigated to assist reactor selection for
continuous biocatalytic pharmaceutical production and a novel selection tool is presented. We have
shown that many reactor configurations, using only the ideal CSTR and CPFR, are possible to ensure
effective enzyme use, overcome inhibitory effects, simplify downstream processing, operate with
multiple phases or control operating conditions like pH, depending on the major limitations of a given
system. Nevertheless, there are other important factors that have yet to be considered, such as:
• Regeneration and retention of expensive cofactors in a continuous reactor;
• Cost-effective and benign methods for retaining enzymes to reduce their overall cost contributions;
• The need for metrics to evaluate and compare different continuous biocatalytic systems;
• Effective downstream unit operations for continuous product isolation and purification.
Future efforts will need to be directed towards these aspects and eventually be used to update the
selection tool presented here.
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Nomenclature
Symbol Definition Unit
CS Substrate concentration mol L−1
CS0 Initial or inlet substrate concentration mol L−1
X Fractional substrate conversion -
t Reaction time s
V Reactor volume L
Q Volumetric flowrate L s−1
KM Substrate affinity constant mol L−1
kcat Enzyme turnover number s−1
τ Residence time s
FS0 Inlet molar flowrate of substrate mol s−1
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